BI 1819479
Alternative Names: BI-1819479Latest Information Update: 28 Apr 2025
At a glance
- Originator Boehringer Ingelheim
- Class Antifibrotics
- Mechanism of Action Lysophospholipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Germany (PO)
- 23 Apr 2025 Phase-II clinical trials in Idiopathic pulmonary fibrosis (PO) before April 2025 (Boehringer Ingelheim pipeline, April 2025)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Germany (PO)